Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Unexpected rosuvastatin-canagliflozin adverse effect reported

Publish date:: August 4, 2020

Key clinical point: A case report cited a patient who developed acute rhabdomyolysis linked with rosuvastatin toxicity within days of starting canagliflozin treatment.

Major finding: The patient showed a plasma rosuvastatin level of 176 ng/mL, more than 15-fold above the mean expected level.

Study details: Case report from a Toronto-area hospital.

Disclosures: The study received no commercial funding. Dr. Juurlink and coauthors had no disclosures.

Citation:

Brailovski E et al. Ann Intern Med. 2020 Aug 3. doi: 10.7326/L20-0549.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,